|
|||||
|
|
The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation |
|
| Authors: | Daneshmand Siamak Stephenson Andrew J Sheinfeld Joel Jewett Michael A S |
| Affiliation: | aUSC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA;bGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA;cDepartment of Urological Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA;dDivision of Urology, Departments of Surgery and of Surgical Oncology, Princess Margaret Hospital and the University Health Network, University of Toronto, Toronto, Ontario M5T 3M4, Canada |
| Abstract: | Patients with advanced non-seminomatous germ cell tumors may achieve a serologic and radiographic complete response (CR) to first-line chemotherapy (defined as a residual mass < 1 cm in size). Recent reports suggest that these patients may be observed with a low rate of relapse but there remain compelling arguments for surgical excision. The arguments for and against post-chemotherapy retroperitoneal lymph node dissection (pcRPLND) are presented. There is clear consensus that patient's with residual masses > 1 cm should undergo post-chemotherapy surgery. |
| Keywords: | Testis cancer Post-chemotherapy retroperitoneal lymph node dissection |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |